Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The segment delivered strong sales growth of 20% YoY
The Visby Medical sexual health click test is the first instrument-free PCR test for the detection of chlamydia, gonorrhoea and trichomonas, with results available within 30 minutes, during the patient visit
This is Enzene Biosciences third biosimilar to be approved
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Domestic business was up 41.9% YoY and 27.7% QoQ
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
It is the first branded generic alternative to Fostair 100/6 pMDI
Subscribe To Our Newsletter & Stay Updated
